Scholar Rock is trading lower as investors weigh uncertainty around the timing of apitegromab’s U.S. approval process, with the company planning to resubmit its biologics license application only after an FDA reinspection related to Catalent’s Indiana fill-finish facility. The market’s sensitivity reflects how tightly SRRK’s near-term value is tied to a clear, de-risked manufacturing and regulatory path for apitegromab.

Apitegromab’s U.S. trajectory has been shaped by manufacturing-related regulatory scrutiny at the Catalent site referenced in the company’s prior FDA Complete Response Letter, and any ambiguity on reinspection timing can translate quickly into day-to-day volatility. Traders are treating incremental updates on readiness for reinspection and the sequencing of BLA resubmission steps as the primary near-term catalyst set.

Scholar Rock has highlighted financing and launch-preparation plans intended to carry the company through regulatory delay and into potential commercialization, including a structured debt facility tied to apitegromab progress and approval-related milestones. With the company still pre-revenue, investors are balancing cash runway and commercialization buildout against the possibility of further timeline slippage if inspections or remediation take longer than expected.